Symposia: Acute Myeloid Leukemias: Commercially Available Therapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Research, Clinical trials, Combination therapy, Apoptosis, Adult, Elderly, Drug development, Clinical Research, Chemotherapy, Diseases, Therapy sequence, Treatment Considerations, Biological therapies, Real-world evidence, Adverse Events, Non-Biological therapies, Young adult , Myeloid Malignancies, Biological Processes, Molecular biology, Study Population, Human, Measurable Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Research, Clinical trials, Combination therapy, Apoptosis, Adult, Elderly, Drug development, Clinical Research, Chemotherapy, Diseases, Therapy sequence, Treatment Considerations, Biological therapies, Real-world evidence, Adverse Events, Non-Biological therapies, Young adult , Myeloid Malignancies, Biological Processes, Molecular biology, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024: 2:00 PM-3:30 PM
Seaport Ballroom EFGH
(Manchester Grand Hyatt San Diego)
Moderators:
Guillaume Richard-Carpentier, MD, FRCPC,
and
John L. Reagan, MD,
Disclosures:
Richard-Carpentier: AbbVie: Honoraria, Other: Advisory Board Participation; Astellas: Honoraria, Other: Advisory Board Participation; Pfizer: Honoraria, Other: Advisory Board Participation; Taiho: Honoraria, Other: Advisory Board Participation; BMS: Other: Advisory Board Participation. Reagan: Sanofi: Consultancy; Pfizer: Research Funding; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees.
2:00 PM
2:15 PM
2:30 PM
2:45 PM
3:00 PM
3:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH